DBV Technologies S.A. (NASDAQ: DBVT)
$3.1400
-0.1550 ( -0.63% ) 23.0K
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Viaskin targets specific antigen-presenting immune cells in the skin, called Langerhans cells, that capture the antigen and migrate to the lymph node to activate the immune system without passage of the antigen into the bloodstream, minimizing systemic exposure in the body. Its main product candidate is Viaskin Peanut for the treatment of peanut-allergic patients.
Market Data
Open
$3.1400
Previous close
$3.2950
Volume
23.0K
Market cap
$64.83M
Day range
$3.0800 - $3.2450
52 week range
$2.2045 - $10.7000
SEC Filings
Form Type | Description | Pages | Date |
---|---|---|---|
8-k | 8K-related | 19 | Oct 22, 2024 |
8-k | 8K-related | 17 | Sep 23, 2024 |
4 | Insider transactions | 1 | Jul 31, 2024 |
10-q | Quarterly Reports | 73 | Jul 30, 2024 |
8-k | 8K-related | 18 | Jul 30, 2024 |
8-k | 8K-related | 14 | Jun 18, 2024 |
8-k | 8K-related | 18 | May 31, 2024 |
4 | Insider transactions | 1 | May 29, 2024 |
8-k | 8K-related | 18 | May 17, 2024 |
8-k | 8K-related | 15 | May 16, 2024 |